ELI LILLY logo

ELI LILLY (LLY)

Market Closed
13 Jun, 20:00
710. 20
+5
+0.71%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
0 Volume
6.64 Eps
705.2
Previous Close
Day Range
693.3 710.2
Year Range
629.4 886.9

Summary

LLY closed yesterday higher at €710.2, an increase of 0.71% from Thursday's close, completing a monthly increase of 0.16% or €1.1. Over the past 12 months, LLY stock lost -4.72%.
LLY pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 2 months on Sep 10, 2025 for a total of €1.5.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports.
ELI LILLY has completed 4 stock splits, with the recent split occurring on Oct 16, 1997.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LLY Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.

Zacks | 1 day ago
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (June 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.

247wallst | 3 days ago
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health

Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health

Research will leverage world's first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discovery of treatments that help individuals maintain and even improve their muscle mass and function REDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, today announced it has entered a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) to discover, develop, and commercialize drug candidates that improve muscle health and body composition.

Globenewswire | 4 days ago

ELI LILLY Dividends

Eli Lilly and Company logo
LLY In 2 months
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 weeks ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share

ELI LILLY Earnings

28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS
8 Aug 2024 Date
2.6
Cons. EPS
3.92
EPS
Eli Lilly and Company logo
LLY In 2 months
Estimated
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 weeks ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 4 months ago
Paid
Quarterly
$1.5 Per Share
Eli Lilly and Company logo
LLY 7 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 10 months ago
Paid
Quarterly
$1.3 Per Share
Eli Lilly and Company logo
LLY 15 May 2024
Paid
Quarterly
$1.3 Per Share
28 Apr 2025 Date
-
Cons. EPS
-
EPS
6 Feb 2025 Date
5.07
Cons. EPS
5.32
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
1.47
Cons. EPS
1.18
EPS
8 Aug 2024 Date
2.6
Cons. EPS
3.92
EPS

ELI LILLY (LLY) FAQ

What is the stock price today?

The current price is €710.20.

On which exchange is it traded?

ELI LILLY is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has ELI LILLY ever had a stock split?

ELI LILLY had 4 splits and the recent split was on Oct 16, 1997.

ELI LILLY Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. David A. Ricks CEO
XHAN Exchange
US5324571083 ISIN
US Country
47,000 Employees
14 Feb 2025 Last Dividend
16 Oct 1997 Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000